| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA889: Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma |
|
Medicine details |
|
| Medicine name | ciltacabtagene autoleucel (Carvykti®) |
| Formulation | intravenous infusion |
| Reference number | 4457 |
| Indication | Treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/04/2022 |
| NICE guidance | TA889: Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma |